Is Pfizer Inc. (PFE) One of the Best Medical Research Stocks to Buy According to Hedge Funds?

1 day ago 4

Noor Ul Ain Rehman

Fri, February 13, 2026 astatine 8:57 AM CST 2 min read

Pfizer Inc. (NYSE:PFE) is 1 of the champion aesculapian probe stocks to bargain according to hedge funds. Pfizer Inc. (NYSE:PFE) announced connected February 6 that the U.S. Food and Drug Administration accepted and granted Priority Review for its supplemental Biologics License Application for HYMPAVZI® for the enlargement of the approved denotation to see attraction of hemophilia A oregon B patients 6 years and older with inhibitors, and pediatric patients with hemophilia A oregon B without inhibitors. HYMPAVZI presently holds support for the attraction of patients 12 years of property and older with hemophilia A without origin VIII inhibitors, oregon hemophilia B without origin IX inhibitors successful the United States.

Pfizer (PFE) Closes 2025 connected  Solid Note, Returns $9.8B to Shareholders

Pfizer (PFE) Closes 2025 connected Solid Note, Returns $9.8B to Shareholders

Pfizer Inc. (NYSE:PFE) further reported that the FDA acceptable a Prescription Drug User Fee Act enactment day successful Q2 2026. If approved, HYMPAVZI would supply a operation of bleed extortion with a straightforward, once-weekly subcutaneous injection medication that requires minimal mentation without a request for regular treatment-related laboratory monitoring for these difficult-to-treat diligent populations.

In different development, Citi reaffirmed its Hold standing connected Pfizer Inc. (NYSE:PFE) connected February 4, mounting a $26 terms target. The institution released its fiscal Q4 and full-year 2025 results connected February 3, announcing full-year revenues of $62.6 billion, reflecting a 2% year-over-year operational decline. It added that revenues grew 6% operationally erstwhile excluding contributions from Paxlovid and Comirnaty. Fiscal Q4 revenues came up to $17.6 billion, highlighting a 3% year-over-year operational decline.

Pfizer Inc. (NYSE:PFE) is simply a planetary biopharmaceutical institution that manufactures, develops, markets, and sells biopharmaceutical products worldwide. It advances wellness, prevention, treatment, and cures successful processing and emerging markets.

While we admit the imaginable of PFE arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you’re looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double successful 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This nonfiction is primitively published at Insider Monkey.

Read Entire Article